Literature DB >> 33335646

Novel CDK2 Inhibitors for Treating Cancer.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2020        PMID： 33335646      PMCID： PMC7734635          DOI： 10.1021/acsmedchemlett.0c00500

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  2 in total

1.  TANK-binding kinase 1 inhibitor GSK8612 enhances daunorubicin sensitivity in acute myeloid leukemia cells via the AKT-CDK2 pathway.

Authors:  Siyu Chen; Ming Ni; Tianzhen Hu; Yangguang Gu; Cheng Feng; Chengyun Pan; Siyu Zhang; Shuangshuang Wen; Naiqin Zhao; Weili Wang; Lihong Dai; Jishi Wang
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

Review 2.  Targeting CDK4 and CDK6 in cancer.

Authors:  Shom Goel; Johann S Bergholz; Jean J Zhao
Journal:  Nat Rev Cancer       Date:  2022-03-18       Impact factor: 69.800
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.